Meeting
2024 ASCO Genitourinary Cancers Symposium
Real-world clinical outcomes of patients treated with Lu-177-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC): A single-institution experience.
Authors
Valeria Maldonado Grijalva
Department of Medicine, Duke University School of Medicine, Durham, NC
Valeria Maldonado Grijalva , John Wang , Marybeth Nedrud , Colm Kelleher , Terence Z. Wong , Matthew Labriola , Hannah Dzimitrowicz McManus
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 83)
DOI
10.1200/JCO.2024.42.4_suppl.83
Abstract #
83
Poster Bd #
C18
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Edmond Michael Kwan
Poster
2024 ASCO Genitourinary Cancers Symposium
Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer.
First Author: Rebecca Hassoun
Poster
2023 ASCO Annual Meeting
PSMA expression and response to 177Lu-PSMA-617 (LuPSMA) in men with vs. without DNA damage repair (DDR) mutations.
First Author: Ruben Raychaudhuri
Poster
2018 Genitourinary Cancers Symposium
Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC).
First Author: Howard I. Scher